Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6791)
All Articles published online
|
Publishing Process of This Article
|
Dec 14, 2018 (publication date) through Apr 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Guerra Veloz MF, Argüelles-Arias F, Castro Laria L, Maldonado Pérez B, Benítez Roldan A, Perea Amarillo R, Merino Bohórquez V, Calleja MA, Caunedo Álvarez Á, Vilches Arenas Á. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease. World J Gastroenterol 2018; 24(46): 5288-5296 [PMID: 30581277 DOI: 10.3748/wjg.v24.i46.5288] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v24/i46/5288.htm |
| Number | Citing Articles |
| 1 |
Eduardo Mysler, Valderilio Feijó Azevedo, Silvio Danese, Daniel Alvarez, Noriko Iikuni, Beverly Ingram, Markus Mueller, Laurent Peyrin-Biroulet. Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?. Drugs 2021; 81(16): 1859 doi: 10.1007/s40265-021-01610-1
|
| 2 |
Ahmad Zainal Abidin, Centaine L. Snoswell, Leila Shafiee Hanjani, Gavin Callaghan, Michelle Edmonds. Infliximab switching from reference product to biosimilar: a review of evidence regarding the clinical efficacy, safety profile and immunogenicity. Journal of Pharmacy Practice and Research 2021; 51(5): 358 doi: 10.1002/jppr.1754
|
| 3 |
Megan McNicol, Mahmoud Abdel‐Rasoul, Madeline G. McClinchie, Grant A. Morris, Brendan Boyle, Jennifer L. Dotson, Hilary K. Michel, Ross M. Maltz. Clinical outcomes and cost savings of a nonmedical switch to a biosimilar in children/young adults with inflammatory bowel disease . Journal of Pediatric Gastroenterology and Nutrition 2024; 78(3): 644 doi: 10.1002/jpn3.12153
|
| 4 |
Bincy Abraham, Bertus Eksteen, Khan Nedd, Hrishikesh Kale, Dipen Patel, Jennifer Stephens, Ahmed Shelbaya, Richard Chambers, Arif Soonasra. Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study). Advances in Therapy 2022; 39(5): 2109 doi: 10.1007/s12325-022-02104-6
|
| 5 |
Rosanne W. Meijboom, Helga Gardarsdottir, Toine C. G. Egberts, Thijs J. Giezen. Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review. BioDrugs 2022; 36(1): 27 doi: 10.1007/s40259-021-00508-4
|
| 6 |
Jinjian Huang, Yanhan Ren, Xiuwen Wu, Zongan Li, Jianan Ren. Gut bioengineering promotes gut repair and pharmaceutical research: a review. Journal of Tissue Engineering 2019; 10: 204173141983984 doi: 10.1177/2041731419839846
|
| 7 |
Stephanie L. Ho, Fang Niu, Suresh Pola, Fernando S. Velayos, Xian Ning, Rita L. Hui. Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study. BioDrugs 2020; 34(3): 395 doi: 10.1007/s40259-020-00409-y
|
| 8 |
Bernd Bokemeyer, Tibor Hlavaty, Matthieu Allez, Pamela Selema, Shahrzad Moosavi, Mary Jane Cadatal, Heather Fowler, Markus Mueller, Katherine F Liau, Javier P Gisbert. Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD). Expert Opinion on Biological Therapy 2023; 23(8): 791 doi: 10.1080/14712598.2023.2200883
|
| 9 |
Gilaad G Kaplan, Christopher Ma, Cynthia H Seow, Karen I Kroeker, Remo Panaccione. The Argument Against a Biosimilar Switch Policy for Infliximab in Patients with Inflammatory Bowel Disease Living in Alberta. Journal of the Canadian Association of Gastroenterology 2020; 3(5): 234 doi: 10.1093/jcag/gwz044
|
| 10 |
Natália Sousa Freitas QUEIROZ, Rogerio SAAD-HOSSNE, Renata de Sá Brito FRÓES, Francisco Guilherme Cancela e PENNA, Stefania Burjack GABRIEL, Adalberta Lima MARTINS, Fabio Vieira TEIXEIRA. DISCONTINUATION RATES FOLLOWING A SWITCH FROM A REFERENCE TO A BIOSIMILAR BIOLOGIC IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS. Arquivos de Gastroenterologia 2020; 57(3): 232 doi: 10.1590/s0004-2803.202000000-45
|